Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

24.81
+1.385.89%
Post-market: 24.810.00000.00%19:36 EDT
Volume:1.44M
Turnover:35.40M
Market Cap:1.10B
PE:-5.74
High:25.50
Open:23.04
Low:23.04
Close:23.43
52wk High:27.22
52wk Low:15.47
Shares:44.20M
Float Shares:25.53M
Volume Ratio:1.69
T/O Rate:5.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3239
EPS(LYR):-4.3239
ROE:-58.88%
ROA:-36.49%
PB:3.57
PE(LYR):-5.74

Loading ...

Dec 04, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 14, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2024

Major Issues Report

Form 8-K - Current report
Nov 12, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 11, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Sep 09, 2024

Major Issues Report

Form 8-K - Current report
Aug 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 15, 2024

Major Issues Report

Form 8-K - Current report
Jul 09, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Jul 09, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Jun 05, 2024

Major Issues Report

Form 8-K - Current report
May 17, 2024

Major Issues Report

Form 8-K - Current report
May 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2024

Major Issues Report

Form 8-K - Current report
Apr 22, 2024

Major Issues Report

Form 8-K - Current report
Mar 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 28, 2024

Major Issues Report

Form 8-K - Current report
Feb 13, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2024

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership